Patents by Inventor Zhonghui Lu
Zhonghui Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11078186Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: November 8, 2017Date of Patent: August 3, 2021Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, Bin Jiang, T. G. Murali Dhar, Zhonghui Lu, Arun Kumar Gupta, Ananta Karmakar
-
Patent number: 10865191Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is —(CR7R7)m—; L2 is —(CR7R7)n—; and X, Z, R1, R2, R3, R4, R5, and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: August 2, 2016Date of Patent: December 15, 2020Assignee: Bristol-Myers Squibb CompanyInventors: Hai-Yun Xiao, T. G. Murali Dhar, Ning Li, Jingwu Duan, Bin Jiang, Zhonghui Lu, Khehyong Ngu, William J. Pitts, Joseph A. Tino
-
Publication number: 20200024257Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: November 8, 2017Publication date: January 23, 2020Inventors: Jingwu DUAN, Bin Jiang, T.G. Murali Dhar, Zhonghui LU, Arun Kumar Gupta, Ananta Karmakar
-
Patent number: 10308652Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: March 17, 2016Date of Patent: June 4, 2019Assignee: Bristol-Myers Squibb CompanyInventors: Stephen T. Wrobleski, Gregory D. Brown, Shuqun Lin, Jingwu Duan, Zhonghui Lu, Murali T. G. Dhar, Hai-Yun Xiao, Andrew J. Tebben
-
Patent number: 10171868Abstract: A method for processing audio data includes: setting a first queue for managing at least one configured information control node of audio data to be played and a second queue for managing at least one configured information control node of played audio data, wherein each of the at least one configured information control node contains attribute information for the audio data to be played; unchaining a unit of the at least one configured information control node from the first queue; reading audio data to be played corresponding to the unit of the at least one configured information control node according to the attribute information for the audio data to be played in the unit of the at least one configured information control node; and chaining the unit of the at least one configured information control node to the second queue.Type: GrantFiled: January 12, 2018Date of Patent: January 1, 2019Assignees: Qingdao Hisense Electronics Co., Ltd., HISENSE INTERNATIONAL CO., LTD., HISENSE USA CORP.Inventors: Zhonghui Lu, Shurong Li, Qiang Wang
-
Publication number: 20180222883Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: A is CR1 or N; B is CR3 or N; D is CR4 or N; L1 is —(CR7R7)m—; L2 is —(CR7R7)n—; and X, Z, R1, R2, R3, R4, R5, and R6 are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: August 2, 2016Publication date: August 9, 2018Inventors: Hai-Yun XIAO, Murali T.G. Dhar, Ning Li, Jingwu Duan, Bin Jiang, Zhonghui Lu, Khehyong Ngu, William J. Pitts, Joseph A. Tino
-
Publication number: 20180139497Abstract: A method for processing audio data includes: setting a first queue for managing at least one configured information control node of audio data to be played and a second queue for managing at least one configured information control node of played audio data, wherein each of the at least one configured information control node contains attribute information for the audio data to be played; unchaining a unit of the at least one configured information control node from the first queue; reading audio data to be played corresponding to the unit of the at least one configured information control node according to the attribute information for the audio data to be played in the unit of the at least one configured information control node; and chaining the unit of the at least one configured information control node to the second queue.Type: ApplicationFiled: January 12, 2018Publication date: May 17, 2018Inventors: Zhonghui LU, Shurong LI, Qiang WANG
-
Publication number: 20180111937Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: ApplicationFiled: March 17, 2016Publication date: April 26, 2018Inventors: Stephen T. WROBLESKI, Gregory D. BROWN, Shuqun LIN, Jingwu DUAN, Zhonghui LU, Murali T.G. DHAR, Hai-Yun XIAO, Andrew J. TEBBEN
-
Patent number: 9771320Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: January 5, 2015Date of Patent: September 26, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Zhonghui Lu, Ananta Karmakar, Arun Kumar Gupta, Carolyn A. Weigelt
-
Patent number: 9725443Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: September 18, 2014Date of Patent: August 8, 2017Assignee: Bristol-Myers Squibb CompanyInventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
-
Patent number: 9708253Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: January 5, 2015Date of Patent: July 18, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu, Carolyn A. Weigelt
-
Patent number: 9663469Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: September 8, 2014Date of Patent: May 30, 2017Assignee: Bristol-Myers Squibb CompanyInventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
-
Patent number: 9637455Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: January 5, 2015Date of Patent: May 2, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu
-
Publication number: 20160326108Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: January 5, 2015Publication date: November 10, 2016Inventors: Jingwu DUAN, T.G.Murali DHAR, Bin JIANG, Zhonghui LU, Hai-Yun XIAO
-
Publication number: 20160326104Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: January 5, 2015Publication date: November 10, 2016Inventors: Jingwu DUAN, T.G.Murali DHAR, Bin JIANG, Ananta KARMAKAR, Arun Kumar GUPTA, Zhonghui LU, Carolyn A. WEIGELT
-
Publication number: 20160326103Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: January 5, 2015Publication date: November 10, 2016Inventors: Jingwu Duan, T.G. Murali Dhar, Bin Jiang, Zhonghui Lu, Ananta Karmakar, Arun Kumar Gupta, Carolyn A. Weigelt
-
Publication number: 20160326115Abstract: Described are ROR? modulators of the formula (I), [INSERT CHEMICAL STRUCTURE HERE] or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: January 5, 2015Publication date: November 10, 2016Inventors: Jingwu Duan, T.G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu
-
Publication number: 20160318870Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: September 8, 2014Publication date: November 3, 2016Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: T.G Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein
-
Patent number: 9458171Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: January 6, 2015Date of Patent: October 4, 2016Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Zhonghui Lu, Hai-Yun Xiao
-
Publication number: 20160229844Abstract: Described are ROR? modulators of the formula (I), or pharmaceutically acceptable salts thereof, wherein all substituents are defined herein. The invention includes stereoisomeric forms of the compounds of formula I, including stereoisomerically-pure, scalemic and racemic form, as well as tautomers thereof. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: September 18, 2014Publication date: August 11, 2016Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: T. G. Murali Dhar, Jingwu Duan, Hua Gong, Bin Jiang, Zhonghui Lu, David S. Weinstein